|
| Primary information |
|---|
| ID | 15252 |
| Therapeutic ID | Th1577 |
| Protein Name | Tilactase |
| Sequence | >Th1577_Tilactase
MKLLSVAAVALLAAQAAGASIKHRLNGFTILEHPDPAKRDLLQDIVTWDDKSLFINGERIMLFSGEVHPFRLPVPSLWLDIFHKIRALGFNCVSFYIDWALLEGKPGDYRAEGIFALEPFFDAAKEAGIYLIARPGSYINAEVSGGGFPGWLQRVNGTLRSSDEPFLKATDNYIANAAAAVAKAQITNGGPVILYQPENEYSGGCCGVKYPDADYMQYVMDQARKADIVVPFISNDASPSGHNAPGSGTSAVDIYGHDSYPLGFDCANPSVWPEGKLPDNFRTLHLEQSPSTPYSLLEFQAGAFDPWGGPGFEKCYALVNHEFSRVFYRNDLSFGVSTFNLYMTFGGTNWGNLGHPGGYTSYDYGSPITETRNVTREKYSDIKLLANFVKASPSYLTATPRNLTTGVYTDTSDLAVTPLIGDSPGSFFVVRHTDYSSQESTSYKLKLPTSAGNLTIPQLEGTLSLNGRDSKIHVVDYNVSGTNIIYSTAEVFTWKKFDGNKVLVLYGGPKEHHELAIASKSNVTIIEGSDSGIVSTRKGSSVIIGWDVSSTRRIVQVGDLRVFLLDRNSAYNYWVPELPTEGTSPGFSTSKTTASSIIVKAGYLLRGAHLDGADLHLTADFNATTPIEVIGAPTGAKNLFVNGEKASHTVDKNGIWSSEVKYAAPEIKLPGLKDLDWKYLDTLPEIKSSYDDSAWVSADLPKTKNTHRPLDTPTSLYSSDYGFHTGYLIYRGHFVANGKESEFFIRTQGGSAFGSSVWLNETYLGSWTGADYAMDGNSTYKLSQLESGKNYVITVVIDNLGLDENWTVGEETMKNPRGILSYKLSGQDASAITWKLTGNLGGEDYQDKVRGPLNEGGLYAERQGFHQPQPPSESWESGSPLEGLSKPGIGFYTAQFDLDLPKGWDVPLYFNFGNNTQAARAQLYVNGYQYGKFTGNVGPQTSFPVPEGILNYRGTNYVALSLWALESDGAKLGSFELSYTTPVLTGYGNVESPEQPKYEQRKGAY
|
| Molecular Weight | 102000 |
| Chemical Formula | NA |
| Isoelectric Point | 4.5 |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | Tilactase half-life at 35ºC is registered to be 123.77 min. This half-life can be affected by temperature in an inversely proportional manner.[A32597] |
| Description | Tilactase is a beta-D-galactosidase obtained from _Aspergillus oryzae_. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal.[A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.[A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338] |
| Indication/Disease | Tilactase is indicated for the symptomatic treatment of lactose intolerance in infants and older patients requiring a parenteral nutrition or fluid diet.[L2338] Lactose intolerance occurs when there is an existence of an inability to break down lactose which is commonly found in dairy products. This inability occurs when the lactase levels are reduced and thus there is no via to digest and break down the lactose. The undigested lactose moves into the large intestine where normal flora bacteria can interact with it and cause bloating, gas and diarrhea.[A32592] |
| Pharmacodynamics | The use of a single oral administration of tilactase has been shown to be highly effective in decreasing the symptoms and hydrogen excretion of hypolactasia in tests of lactose H(2)-breath. The analysis has shown a decrease of approximately 80% in both malabsorbers and intolerants.[A27172]The administration of tilacatase also decreases the presence of bloating and flatus.[A27173] |
| Mechanism of Action | Lactose is the primary disaccharide found in dairy products. Tilactase is a type of lactase which is the enzyme that is in charge of the breakdown of lactose to glucose and galactose which can be used by the body.[L2340] Basically, tilactase acts by replacing the missing lactase in the body and allows avoidance of the reach of lactose to the small intestine and the normal bacteria and thus, preventing the symptoms of the lactose intolerance. Once tilactase has metabolized the lactose, the metabolism products are reabsorbed by the normal process of digestion.[L2345] |
| Toxicity | Tilactase is known to present a low acute oral toxicity in preclinical trials. The lowest toxic dose for subcutaneous exposure is of 26 g/kg administered over 30 days.[L2340] There have not been performed enough studies regarding the use of pregnancy or related to the fetal development. There are no reports of overdose with tilactase.[L2345] |
| Metabolism | Tilactase is degraded by the stomach acid and by the normal flora bacterial metabolism.[L2345] |
| Absorption | Tilactase is not absorbed in the GI tract and thus the pharmacokinetic parameters related to absorption are not relevant.[L2345] |
| Tilactase is not absorbed and thus the volume of distribution is not relevant. |
| Clearance | Tilactase is not absorbed and thus the clearance rate is not relevant. |
| Categories | Enzymes and Coenzymes |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Lactose |
| Brand Name | Lactase Enzyme |
| Company | Holista Health (Canada) Inc. |
| Brand Description | Holista Health (Canada) Inc. |
| Prescribed For | Oral |
| Chemical Name | 3300 unit / cap |
| Formulation | NA |
| Physical Appearance | hives; difficult breathing; swelling of your face, lips, tongue, or throat. |
| Route of Administration | Lactase is often sold as a dietary supplement. There are no regulated manufacturing standards in place for supplements and some marketed products have been found to be contaminated with toxic metals or other drugs. Dietary supplements should be purchased from a reliable source to minimize the risk of contamination. |
| Recommended Dosage | Lactase is an enzyme that helps your body break down lactose in dairy products. If you are lactose-intolerant, consuming a dairy product can cause gas, bloating, stomach pain, or diarrhea. |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | Link |
| Remarks | NA |